Pancreas before Kidney Transplant in Diabetic Patients with Uremia

Bor-Wei Shyr

Taipei Veterans General Hospital; National Yang Ming Chiao Tung University

Bor-Shiuan Shyr

Taipei Veterans General Hospital; National Yang Ming Chiao Tung University

Shih-Chin Chen

Taipei Veterans General Hospital; National Yang Ming Chiao Tung University

Yi-Ming Shyr

Taipei Veterans General Hospital; National Yang Ming Chiao Tung University

Shin-E Wang (✉ sewang0408@gmail.com)

Taipei Veterans General Hospital; National Yang Ming Chiao Tung University

Research Article

Keywords: pancreas before kidney transplant (PBK), pancreas after kidney transplant (PAK), simultaneous kidney pancreas transplant (SPK), pancreas transplant alone (PTA)

Posted Date: June 9th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-579293/v1>

License: This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Abstract

Theoretically, pancreas before kidney transplant (PBK) could also be one of the options for those waiting for both pancreas and kidney grafts, but it has never been reported. This study is to clarify the justification and feasibility of PBK. There were 160 cases of pancreas transplant in this study, including 26 (16%) PBK. Rejection (3.8%) of pancreas graft was significantly lower in PBK group, followed by 16.7% in pancreas after kidney transplant (PAK), 29.8% in simultaneous pancreas and kidney transplant (SPK) and 37.0% in pancreas transplant alone (PTA). There was no chronic rejection in PBK and PAK groups. Fasting blood sugar and serum HbA1c levels after PBK were not significantly different from those by other subgroups. The serum C-peptide levels were significantly higher in PBK group than those by other subgroups. The 5-year pancreas graft survival was 100% for PBK and PAK, 97.0% for SPK and 77.9% for PTA. In conclusion, PBK could be a treatment option for patients with diabetes complicated by end-stage renal disease (ESRD) in terms of surgical risks, endocrine function, and immunological and graft survival outcomes. However, given the inferior patient survival outcome, PBK is still not recommended unless SPK and PAK is not available.

Introduction

Pancreas transplant remains the best option of treatment to achieve long-term physiological euglycemia and insulin independence for patients with labile diabetes mellitus (DM) such as type 1 DM (T1DM). Traditionally, pancreas transplant has been reserved for diabetic patients with end-stage renal disease (ESRD), undergoing simultaneous pancreas-kidney transplant (SPK), and previously receiving a kidney graft and pancreas after kidney transplant (PAK), or those with brittle diabetes without uremia, undergoing pancreas transplant alone (PTA)¹⁻³. For patients with labile DM and ESRD, SPK would be a preferred treatment because it can simultaneously provide an insulin-free and dialysis-free life for patients during the same operation⁴⁻⁹. Nevertheless, SPK has also been claimed to have the best long-term outcome in diabetic cases with renal failure^{10,11}. However, pancreas and kidney transplants are not necessarily to be accomplished at the same time because both pancreas and kidney are not vital organs. Kidney transplant is the well-known treatment of choice for ESRD patients. However, in diabetic patients, the underlying metabolic disturbance will persist and even may get worse after isolated kidney transplant¹⁰. Currently, PAK has also been an acceptable option for those previously receiving a kidney graft in many centers^{1,12,13}. According to the updated Scientific Registry of Transplant Recipients (SRTR) reports¹⁻³, majority of the pancreas transplants are for SPK (81% ~ 84%), followed by PTA (9% ~ 11%) and PAK (7% ~ 8%). Theoretically, pancreas before kidney transplant (PBK) could also be one of the options for those waiting for both pancreas and kidney grafts. To our knowledge, PBK has never been reported in the literature.

For diabetic patients with uremia, SPK is undoubtedly the preferred option, and kidney transplant first in PAK is also well documented choice, but how about pancreas transplant first in PBK? Therefore, the aim of this work was to assess the feasibility and justification of pancreas transplant first in the diabetic patients with uremia, PBK group, by comparing the surgical risks and outcomes of endocrine, immunology, and

pancreas graft survival between PBK and other traditional transplant subgroups. This work would be the first study regarding the PBK.

Methods

Diabetes patients undergoing pancreas transplant from September of 2003 to May of 2020 were included in this study. Perioperative and follow-up data for each patient were prospectively collected and kept in a computer database. This study was approved by our institutional review board (IRB), Institutional Review Board, Taipei Veterans General Hospital, (IRB-TPEVGH No.: 2020-05-006CC). The study was carried out in accordance with our IRB guidelines and regulations. The informed consent was waived in this retrospective cohort study with anonymity of the data by our institutional review board. The official indications for pancreas transplant in Taiwan include the following: (1) T1DM with diabetic complications such as nephropathy, retinopathy, neuropathy, and cardio-cerebral vasculopathy; (2) T1DM with frequent life-threatening hypoglycemia or hyperglycemia; (3) T1DM with severe disability in school learning, working, and living; and (4) type 2 DM (T2DM) with kidney disease leading to ESRD under insulin control with insulin requirement of less than 1.5 units/kg/day. Based on the patient's condition, pancreas transplants were classified into 4 subgroups at our institute: PBK, pancreas before kidney transplant; SPK, simultaneous pancreas-kidney transplant; PAK, pancreas after kidney transplant; PTA, pancreas transplant alone. According to the regulations of Taiwan Organ Registry and Sharing Center, the waiting lists for pancreas and kidney grafts are separate, and there are always more than 7,000 uremic patients waiting for a kidney graft, but only about 100 diabetic patients waiting for a pancreas graft (assessed on June 1, 2021 at https://www.torsc.org.tw/about/about_08.jsp). There is always more competition for kidney grafts from deceased donors in our country. A diabetic patient with ESRD might not have pancreas and kidney transplanted at the same time, and some patients who actually needed SPK would even accept pancreas transplant first, so called PBK, after the procedure is fully explained.

Clinical data and outcomes including early (before discharge) and late (after discharge) complications, surgical mortality, acute and chronic rejections, graft loss, fasting blood sugar, serum hemoglobin A1c (HbA1c), serum C-peptide, and pancreas graft survival were compared between each subgroup of pancreas transplant. In this study, surgical mortality was defined as postoperative death before discharge or within 90 days after operation. Any return to insulin use was counted as pancreas graft failure. Graft loss due to patient death with functioning graft was considered as censor, not event of interest, in graft survival analysis.

The primary endpoints were comparisons of pancreas transplant first in PBK group to other subgroups in terms of endocrine function, immunological, and graft survival outcomes. The secondary endpoints were comparisons of pancreas transplant first in PBK group to other subgroups in terms of surgical outcomes and patient survival.

Patients with a positive crossmatch against donor cells were excluded for pancreas transplant. The pancreas grafts were procured in a “no touch” technique en bloc with the duodenum. The spleen was routinely separated from the pancreas before aorta cross-clamping. Histidine-tryptophan-ketoglutarate

solution was used for in situ perfusion, with 4,000 to 6,000 c.c. via aorta and 2,000 to 4,000 c.c. via inferior mesenteric vein. Back-table bench preparation included removal of the peripancreatic fat and arterial Y-graft reconstruction. The graft portal vein was anastomosed end-to-side to the recipient's distal vena cava with head-up position of the pancreas graft. The superior mesenteric and splenic arteries reconstructed by donor iliac arterial Y-graft at the back-table was anastomosed to the recipient's right common iliac or external iliac artery. Exocrine drainage was achieved by enteric drainage with a hand-sewn side-to-side duodenojejunostomy 30–50 cm beyond the flexure of Treitz ligament using roux-en-Y technique and retroperitoneal placement.

Immunosuppressive treatment was quadruple therapy for all recipients of pancreas transplantation without any specific protocol for each subgroup. Induction therapy included basiliximab (Simulect, Novartis Pharmaceuticals Corp., East Hanover, NJ), 20 mg given on postoperative days 0 to 4, or anti-thymocyte globulin (Thymoglobulin®; Genzyme, Cambridge, Mass., USA) for high risk of rejection such as positive panel-reactive antibody (PRA) and re-transplant, 1 mg/kg daily from postoperative days 1 to 7. Maintenance therapy mainly included administration of tacrolimus (Prograf; Astellas Pharma US, Inc., Deerfield, IL), enteric-coated mycophenolic acid (Myfortic; Novartis Pharmaceuticals Corp., East Hanover, NJ), and prednisolone. Prednisolone was tapered and gradually withdrawn 6 months after transplant. The target trough level for tacrolimus was 8–12 ng/mL during the first year and 6–8 ng/mL thereafter.

Statistical analyses were performed using Statistical Product and Service Solutions (SPSS) version 21.0 software (SPSS Inc., IBM, Armonk, NY, USA). All continuous data were presented as median and mean $\pm$ standard deviation (SD), and frequencies were presented when appropriate to the type of data. The mean values of the continuous variables were compared using a two-tailed Student's t-test. Nonparametric statistical tests were used if the variables did not follow normal distribution. Categorical variables were presented as numbers and percentages. Categorical variables were compared using Pearson's χ^2 test or Fisher's exact test contingency tables. Actuarial graft survival rates were estimated using the Kaplan-Meier method, excluding the primary graft failure and surgical mortality. The log-rank test was used to compare differences in the survival curves. For all analyses, $P < 0.05$ was considered to be statistically significant.

Results

A total of 160 cases of pancreas transplant were included in this study, including 26 (16%) PBK, 37 (23%) SPK, 24 PAK (15%), and 73 (46%) PTA (Table 1). There was no significant difference between PBK and other subgroups regarding gender, body mass index (BMI), human leukocyte antigen (HLA) mismatch, pretransplant panel reactive antibody (PRA), DM onset age, and dialysis duration, but younger age and shorter DM duration in PTA group as compared with other subgroups with ESRD. Among PBK group, 13 (50%) patients were type 2 DM, significantly higher as compared with other subgroups, $P < 0.001$.

Table 1
Demographics for diabetic patients undergoing pancreas transplant

	Total	PBK	SPK	PAK	PTA	P-value
Case number	160	26 (16%)	37 (23%)	24 (15%)	73 (46%)	
Gender						0.128
Female	90 (56%)	13 (50%)	16 (43%)	13 (54%)	48 (66%)	
Age, y/o	33	33	37	38	30	< 0.001
Median	16–58	25–55	26–58	20–55	16–56	
Range	34 ± 9	36 ± 7	38 ± 8	37 ± 9	31 ± 8	
Mean ± SD						
BMI, kg/m ²	21.6	22.0	21.0	22.2	21.0	0.801
Median	12.0–34.1	16.0–30.0	17.1–34.1	16.0–29.0	12.0–31.1	
Range					21.6 ± 3.4	
Mean ± SD	21.9 ± 3.5	22.2 ± 3.0	22.0 ± 4.0	22.3 ± 3.4		
Type 2 DM	32 (20%)	13 (50%)	11 (30%)	6 (25%)	2 (3%)	< 0.001
HLA mismatch	3	3	3	3	3	0.472
Median	0–5	0–4	0–5	1–4	0–5	
Range	3 ± 1	3 ± 1	3 ± 1	3 ± 1	3 ± 1	
Mean ± SD						
PRA Positive (> 0%)	27 (17%)	6 (23%)	1 (3%)	6 (25%)	14 (19%)	0.060
DM onset age, year old	15	13	17	15	14	0.424
Median	1–43	4–36	8–40	5–28	1–43	
Range	16 ± 8	16 ± 7	18 ± 8	15 ± 6	16 ± 8	
Mean ± SD						

PBK: pancreas before kidney transplant; SPK: simultaneous pancreas and kidney transplant; PTA: pancreas transplant alone; PAK: pancreas after kidney transplant; BMI: body mass index; HLA: human leukocyte antigen; PRA: panel reactive antibody; DM: diabetes mellitus

	Total	PBK	SPK	PAK	PTA	<i>P</i> -value
DM duration, year	18	21	20	22	14	< 0.001
Median	1–39	7–32	5–39	3–34	1–32	
Range	17 ± 8	20 ± 5	19 ± 7	22 ± 8	14 ± 7	
Mean ± SD						
Dialysis duration, month	18.0	19.0	15.0	29.0	N/A	0.181
Median	0.8–168.0	2.0–60.0	0.8–72.0	3.0–168.0		
Range	25.5 ± 26.6	25.5 ± 26.6	23.3 ± 23.7	36.8 ± 42.9		
Mean ± SD						
PBK: pancreas before kidney transplant; SPK: simultaneous pancreas and kidney transplant; PTA: pancreas transplant alone; PAK: pancreas after kidney transplant; BMI: body mass index; HLA: human leukocyte antigen; PRA: panel reactive antibody; DM: diabetes mellitus						

The surgical and immunological outcomes were listed in Table 2. There was no significant difference in surgical outcomes between PBK and other subgroups including cold ischemic time, warm ischemic time, overall complications, surgical mortality, hospital stay and cost. The early complication was lower in PTA group as compared with other subgroups with ESRD. Rejection of pancreas graft was much lower, 3.8% in PBK group, followed by 16.7% in PAK, 29.8% in SPK and 37.0% in PTA, *P* = 0.006. There was no chronic rejection in PBK and PAK groups, *P* = 0.045. Pancreas graft loss rate was higher (38.5%) in PBK and PTA groups, *P* < 0.001. Majority (9/10) of pancreas graft loss in PBK group was due to patient death with functioning graft (34.6%) and the remaining one (1/10) was resulted from technical failure with graft hemorrhage (3.8%) after revascularization of graft during operation. Majority (16/28) of pancreas graft loss in PTA group was chronic rejection (21.9%).

Table 2
Surgical and immunological outcomes for diabetic patients after pancreas transplant

	Total	PBK	SPK	PAK	PTA	P-value
Case number	160	26 (16%)	37 (23%)	24 (15%)	73 (46%)	
Cold ischemic time, min.						0.483
Median	370	367	450	355	360	
Range	102–995	192–624	228–767	163–995	102–736	
Mean ± SD	399 ± 150	368 ± 127	466 ± 147	379 ± 172	382 ± 145	
Warm ischemic time, min.						0.412
Median	38	38	39	37	37	
Range	23–86	25–49	27–60	27–67	23–86	
Mean ± SD	39 ± 10	37 ± 6	41 ± 8	40 ± 11	39 ± 11	
Complications	112 (70.0%)	18 (69.2%)	30 (81.1%)	17 (70.8%)	47 (64.4%)	0.351
Early complication	74 (46.3%)	13 (50.0%)	23 (62.2%)	15 (62.5%)	23 (31.5%)	0.005
Late complication	79 (49.4%)	10 (38.5%)	21 (56.8%)	10 (41.7%)	38 (52.1.0%)	0.419
Surgical mortality	4 (2.5%)	1 (3.8%)	1 (2.7%)	2 (8.3%)	0	0.143
Rejection	41 (25.6%)	1 (3.8%)	9 (24.3%)	4 (16.7%)	27 (37.0%)	0.006
Acute rejection	30 (18.8%)	1 (3.8%)	6 (16.2%)	4 (16.7%)	19 (26.0%)	0.088
Chronic rejection	15 (9.4%)	0	4 (10.8%)	0	11 (15.1%)	0.045
Graft loss	54 (33.8%)	10 (38.5%)	11 (29.8%)	5 (20.8%)	28 (38.4%)	< 0.001
Acute rejection	7 (4.4%)	0	1 (2.7%)	0	6 (8.2%)	

PBK: pancreas before kidney transplant; SPK: simultaneous pancreas and kidney transplant; PTA: pancreas transplant alone; PAK: pancreas after kidney transplant; USD: United States Dollar

	Total	PBK	SPK	PAK	PTA	<i>P</i> -value
Chronic rejection	21 (13.1%)	0	5 (13.5%)	0	16 (21.9%)	
Death with functioning graft	18 (11.3%)	9 (34.6%)	4 (10.8%)	2 (8.3%)	3 (4.1%)	
Graft hemorrhage	3 (1.9%)	1 (3.8%)	0	2 (8.3%)	0	
Primary nonfunction	3 (1.9%)	0	1 (2.7%)	1 (4.2%)	1 (1.4%)	
Unknown	2 (1.3%)	0	0	0	2 (2.7%)	
Hospital stay, day						0.423
Median	15	16	17	19	12	
Range	7–112	9–78	7–112	8–60	8–68	
Mean ± SD	19 ± 14	23 ± 16	21 ± 17	23 ± 13	16 ± 11	
Hospital cost, USD						0.471
Median	25,024	27,608	26,952	28,793	22,747	
Range	13,926–63,623	21,862–48,342	15,625–60,466	17,533–51,229	13,926–63,623	
Mean ± SD	26,775 ± 8,729	30,191 ± 7,839	28,745 ± 9,102	28,958 ± 9,102	24,083 ± 7,572	
PBK: pancreas before kidney transplant; SPK: simultaneous pancreas and kidney transplant; PTA: pancreas transplant alone; PAK: pancreas after kidney transplant; USD: United States Dollar						

The short-term and long-term fasting blood sugar (FBS) values after PBK were not significantly different from those by other pancreas transplant subgroups (Fig. 1a). There was also no significant difference regarding the serum hemoglobin A1c (HbA1c) levels between each subgroups at each post-transplant follow-up time, except that at 1 year follow-up after PBK, with a median HbA1c of 5.1%, significantly lower than other subgroups, $P = 0.003$ (Fig. 1b). The serum C-peptide levels were significantly higher in PBK group than those by other pancreas transplant subgroups at each post-transplant follow-up time (Fig. 1c).

Pancreas graft survival outcome after PTA was worse than other pancreas transplant subgroups, $P < 0.001$ (Fig. 2a). The 5-year pancreas graft survival was 100% after PBK and PAK, and 97.0% after SPK and 77.9% after PTA (Table 3). Patient survival outcome after PBK was worse than other pancreas transplant subgroups (Fig. 2b). The 5-year pancreas graft survival was 66.2% after PBK, 94.5% after SPK, 95.8% after

PAK, and 95.4% after PTA (Table 4). The causes of patient death in PBK group included 3 cerebrovascular accident, 2 acute myocardial infarction, 2 sepsis, 1 hepatic failure due to hepatitis and 1 unknown cause.

Table 3
Survival of pancreas grafts after pancreas transplant

	Total	PBK	SPK	PAK	PTA	<i>P</i> -value
Case number	150	23	35	19	73	< 0.001
Median, month	66	44	118	62	62	
Range, month	2–200	3–124	10–200	6–174	2–156	
Mean ± SD, month	75.9 ± 49.0	50.4 ± 36.2	113.5 ± 49.7	72.7 ± 46.9	66.8 ± 43.4	
1-year survival	97.9%	100%	100%	100%	95.9%	
5-year survival	88.2%	100%	97.0%	100%	77.9%	
10-year survival	70.6%	N/A	89.1%	100%	48.1%	
PBK: pancreas before kidney transplant; SPK: simultaneous pancreas and kidney transplant; PTA: pancreas transplant alone; PAK: pancreas after kidney transplant; N/A: not available; technique failure was not included; Graft loss due to patient death with functioning graft was considered as censor						

Table 4
Survivals for patients after pancreas transplant

	Total	PBK	SPK	PAK	PTA	<i>P</i> -value
Case number	160	26	37	24	73	< 0.001
Median, month	87	42	129	68	86	
Range, month	0.3–203	1–124	10–203	0.3–174	7–165	
Mean ± SD, month	88.1 ± 53.0	49.0 ± 38.5	125.2 ± 51.0	74.2 ± 47.3	87.7 ± 48.7	
1-year survival	95.6%	80.4%	97.3%	95.8%	100%	
5-year survival	90.6%	66.2%	94.5%	95.8%	95.4%	
10-year survival	88.8%	66.2%	94.5%	95.8%	95.4%	
PBK: pancreas before kidney transplant; SPK: simultaneous pancreas and kidney transplant; PTA: pancreas transplant alone; PAK: pancreas after kidney transplant; Surgical mortality was included.						

Discussion

Pancreas transplant remains the most effective option of treatment to achieve and maintain physiological euglycemia, and, moreover, to halt or even potentially reverse the secondary complications related to diabetes. Significant improvements in quality of life and better life expectancy make it in the longer term, a

lifesaving procedure compared to waiting candidates¹⁴. For diabetic patients with ESRD, SPK has been a standard treatment to provide a healthier lifestyle without the burden of dialysis and insulin therapy^{4,10}. Pancreas graft allocation system may be different from country to country^{1,4,10,15}. The new pancreas allocation system went into effect on October 30, 2014 in the America, run by Organ Procurement and Transplantation Network (OPTN)/United Network for Organ Sharing (UNOS)¹⁵. All solid-organ pancreas transplant types (SPK, PTA, and PAK) were combined into a single waiting list¹⁵. According to OPTN/SRTR 2018 Annual Data Report, 84% of pancreas transplants were SPK, 9% PTA, and 7% PAK¹. No PBK has been reported in the literature to date. In Taiwan, the pancreas and kidney allocation systems are different. Pancreas and kidney waiting lists are not combined together, and the diabetic candidates (about 100 patients) on the pancreas waiting list are always much outnumbered by uremic candidates (> 7,000 patients) on the kidney waiting list (assessed on June 1, 2021 at https://www.torsc.org.tw/about/about_08.jsp). Therefore, there is more competition for kidney grafts from deceased donors in Taiwan; a diabetic patient with ESRD might not have pancreas and kidney transplanted at the same time, and some patients who actually needed SPK would even undergo PBK. These PBK patients after pancreas transplant first in diabetic patient with uremia are still on the regular kidney transplant waiting list according to Taiwan organ allocation system.

Technically, PBK could be performed with similar operation times (cold and warm ischemic times) and without increasing surgical risks in terms of surgical morbidity and mortality, as compared with other pancreas transplant subgroups. Meanwhile, PBK did not significantly increase the hospital stay and cost. According to OPTN/SRTR 2018 Annual Data Report¹, incidence of a first rejection episode 1 year after pancreas transplant was 12.4% for SPK, 19.2% for PTA and 11.7% for PAK respectively. The higher incidence of rejection after PTA might reflect a trend toward protocol biopsies based on historically higher incidence of rejection and lack of reliable markers for rejection in the absence of a simultaneously transplanted kidney¹. This study also showed higher incidence of both acute (26.0%) and chronic (15.1%) rejection in PTA group; however, only 1 case of acute rejection (3.8%) and 0% chronic rejection occurred in PBK. Although both PBK and PTA were eventually associated with higher graft loss rate, 38.5% and 38.4% respectively, the causes of graft loss for these two groups were different. Most of graft loss in PTA group resulted from rejection (30.1%), including chronic (21.9%) and acute (8.2%) rejection, whereas the leading cause of graft loss in PBK group was patient death with functioning graft (34.6%). It has been claimed that uremia-associated immune deficiency is a well-known complication of loss of renal function and contributes significantly to the overall mortality and morbidity of patients with ESRD^{16,17}. Immunologically, ESRD is associated with functional defects in virtually all cell populations of both the innate and adaptive immune systems. The ESRD-related changes in the immune system resemble immunological aging in the very old healthy individuals, a concept known as premature immunological aging¹⁶⁻¹⁸. Chronic inflammation and increased oxidative stress probably contribute to the underlying the uremia-associated immune deficiency. Although these disorders are complex, yet thoroughly unknown, the uremia-associated immune deficiency would result in a decreased vaccination response, cardiovascular events, more infections and increased susceptibility for malignancies^{16,17,19,20}. Therefore, the low graft rejection in PBK patients might be a reflection of the underlying uremia-associated immune deficiency/inertia. In the

other hand, the uremia-associated immune deficiency might play a substantial role in the clinical implications, and could be the main contributing factor for the higher rate of patient death with functioning graft after a successful PBK in this study.

Endocrine function of the pancreas graft would be the prime concern after pancreas transplants. PBK could also effectively provide similar endocrine function in terms of fasting blood sugar and HbA1c levels, compared to other pancreas transplant subgroups in this study. Nevertheless, the serum c-peptide levels in PBK group are even significantly higher than those in other pancreas transplant subgroups. This finding of higher serum c-peptide levels could be a reflection of more T2DM patients (50%) in PBK groups because T2DM patients tend to be associated with hyperinsulinemia²¹. In other words, it implies that PBK could also work well in T2DM patients.

Pancreas graft survival outcome after PBK is essentially similar to SPK and PAK, and superior to PTA by our study. These findings imply that the uremia-associated immune deficiency/inertia in PBK, SPK and PAK patients might play a role in the lower incidence of rejection, which contributes to the better graft survival outcome, as compared with PTA group. However, patient survival outcome in PBK group is inferior to other pancreas transplant subgroups. PBK patients with unresolving uremic condition seem to be more vulnerable to cardiac events, cerebrovascular accidents, infections and malignancies, like seen in our series. These risks could be attributed to the underlying uremia-associated immune deficiency as mentioned earlier^{16,17,19,20}. It seems that the uremia-associated immune deficiency/inertia in PBK patients would trade a superior pancreas graft survival for an inferior patient survival outcome. Therefore, subsequent kidney transplant following a successful pancreas transplant should be encouraged whenever possible.

Limitation of this study is no data of kidney grafts to be presented in PBK group. It has been very competitive for our uremic patients to have a kidney graft for transplant because the pancreas and kidney waiting lists are separate according to our organ allocation policy. Actually, no one in PBK group undergoes subsequent kidney transplant so far during the follow-up period although they had been kept waiting for that. Therefore, the term "PBK" would be some kind of misnomer without subsequent kidney transplant.

Conclusion

PBK could be a treatment option for patients with diabetes complicated by ESRD in terms of surgical risks, endocrine function, and immunological and graft survival outcomes. However, given the inferior patient survival outcome, PBK is still not recommended unless SPK and PAK is not available due to constraints from the kidney allocation policies. Therefore, the rationale for PBK would be amelioration of short-term diabetic morbidity to allow for patients to remain medically stable to wait for a kidney transplant and also to further avoid the long-term complications associated with DM, and also seen in SPK and PAK patients. Nevertheless, subsequent kidney transplant following successful pancreas transplant should be encouraged whenever possible because PBK patients might be more vulnerable to cardiac events, cerebrovascular accident, infection, and malignancy.

Abbreviations

DM diabetes mellitus

T1DM type 1 DM

PBK pancreas before kidney transplant

SPK simultaneous pancreas-kidney transplant

PAK kidney graft and pancreas after kidney transplant

PTA pancreas transplant alone

BMI body mass index

HLA human leukocyte antigen

C-peptide connecting-peptide

SRTR Scientific Registry of Transplant Recipients

ESRD end-stage renal disease

HbA1c hemoglobin A1c

PRA panel reactive antibody

Declarations

Acknowledgments

The authors would like to acknowledge the support of the Biobank of Taipei Veterans General Hospital. This work is financially supported by grants from the Taipei Veterans General Hospital (V110B-023, V110C-010 and V110C-011), the Ministry of Science and Technology (MOST 108-2314-B-075 -051 -MY3), and the Ministry of Health and Welfare (MOHW107-TDU-B-212-114026A).

Author Contributions

S.-E.W. and Y.-M. S contribute equally to this work and are corresponding co-authors. B.-U. S., B.-S. S., S.-C. C., Y.-M. S and S.-E.W. contributed to each of the followings: (1) substantial contribution to conception and design, acquisition of data, and analysis and interpretation of data; (2) drafting the article, and (3) final approval of the version to be published.

Competing interests

The authors declare no competing interests.

Data availability statement

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

References

1. Kandaswamy, R. *et al.* OPTN/SRTR 2018 Annual Data Report: Pancreas. *Am J Transplant* **20 Suppl s1**, 131–192, doi:10.1111/ajt.15673 (2020).
2. Kandaswamy, R. *et al.* OPTN/SRTR 2017 Annual Data Report: Pancreas. *Am J Transplant* **19 Suppl 2**, 124–183, doi:10.1111/ajt.15275 (2019).
3. Kandaswamy, R. *et al.* OPTN/SRTR 2016 Annual Data Report: Pancreas. *Am J Transplant* **18 Suppl 1**, 114–171, doi:10.1111/ajt.14558 (2018).
4. Posegger, K. R. *et al.* The quality of life in type I diabetic patients with end-stage kidney disease before and after simultaneous pancreas-kidney transplantation: a single-center prospective study. *Transpl Int* **33**, 330–339, doi:10.1111/tri.13562 (2020).
5. Kaufman, D. B. & Sutherland, D. E. Simultaneous pancreas-kidney transplants are appropriate in insulin-treated candidates with uremia regardless of diabetes type. *Clin J Am Soc Nephrol* **6**, 957–959, doi:10.2215/cjn.03180411 (2011).
6. Light, J. & Tucker, M. Simultaneous pancreas kidney transplants in diabetic patients with end-stage renal disease: the 20-yr experience. *Clin Transplant* **27**, E256-263, doi:10.1111/ctr.12100 (2013).
7. Parajuli, S. *et al.* More than 25 years of pancreas graft survival after simultaneous pancreas and kidney transplantation: experience from the world's largest series of long-term survivors. *Transplantation*, doi:10.1097/tp.0000000000002960 (2019).
8. Sampaio, M. S., Kuo, H. T. & Bunnapradist, S. Outcomes of simultaneous pancreas-kidney transplantation in type 2 diabetic recipients. *Clin J Am Soc Nephrol* **6**, 1198–1206, doi:10.2215/CJN.06860810 (2011).
9. Chakkera, H. A. *et al.* Outcomes after simultaneous pancreas and kidney transplantation and the discriminative ability of the C-peptide measurement pretransplant among type 1 and type 2 diabetes mellitus. *Transplant Proc* **42**, 2650–2652, doi:10.1016/j.transproceed.2010.04.065 (2010).
10. Aref, A., Zayan, T., Pararajasingam, R., Sharma, A. & Halawa, A. Pancreatic transplantation: Brief review of the current evidence. *World J Transplant* **9**, 81–93, doi:10.5500/wjt.v9.i4.81 (2019).
11. Margreiter, C. *et al.* Combined pancreas-kidney transplantation for patients with end-stage nephropathy caused by type-2 diabetes mellitus. *Transplantation* **95**, 1030–1036, doi:10.1097/TP.0b013e3182861945 (2013).

12. Parajuli, S. *et al.* Outcomes after simultaneous kidney-pancreas versus pancreas after kidney transplantation in the current era. *Clin Transplant* **33**, e13732, doi:10.1111/ctr.13732 (2019).
13. Gruessner, A. C. & Gruessner, R. W. Pancreas Transplantation of US and Non-US Cases from 2005 to 2014 as Reported to the United Network for Organ Sharing (UNOS) and the International Pancreas Transplant Registry (IPTR). *Rev Diabet Stud* **13**, 35–58, doi:10.1900/RDS.2016.13.e2016002 1900/rds.2016.13.35 (2016).
14. Dholakia, S. *et al.* The rise and potential fall of pancreas transplantation. *Br Med Bull* **124**, 171–179, doi:10.1093/bmb/ldx039 (2017).
15. Kandaswamy, R. *et al.* Pancreas. *Am J Transplant* **16 Suppl 2**, 47–68, doi:10.1111/ajt.13667 (2016).
16. Betjes, M. G. Uremia-Associated Ageing of the Thymus and Adaptive Immune Responses. *Toxins (Basel)* **12**, doi:10.3390/toxins12040224 (2020).
17. Betjes, M. G., Meijers, R. W. & Litjens, N. H. Loss of renal function causes premature aging of the immune system. *Blood Purif* **36**, 173–178, doi:10.1159/000356084 (2013).
18. Crepin, T. *et al.* Uraemia-induced immune senescence and clinical outcomes in chronic kidney disease patients. *Nephrol Dial Transplant* **35**, 624–632, doi:10.1093/ndt/gfy276 (2020).
19. Nongnuch, A. *et al.* Immune response to influenza vaccination in ESRD patients undergoing hemodialysis vs. hemodiafiltration. *PLoS One* **15**, e0227719, doi:10.1371/journal.pone.0227719 (2020).
20. Sharif, M. R. *et al.* Immune disorders in hemodialysis patients. *Iran J Kidney Dis* **9**, 84–96 (2015).
21. Banu, S., Jabir, N. R., Manjunath, C. N., Shakil, S. & Kamal, M. A. C-peptide and its correlation to parameters of insulin resistance in the metabolic syndrome. *CNS Neurol Disord Drug Targets* **10**, 921–927, doi:10.2174/187152711799219271 (2011).

Figures

Figure 1

Endocrine function after pancreas transplants. (1a) Fasting blood sugar (FBS) levels after pancreas transplants. (1b) Hemoglobin A1c (HbA1c) levels after pancreas transplants. (1c) Serum C-peptide levels after pancreas transplants. PT 0: post-transplant day 0, PTD: post-transplant day, PTM: post-transplant month, PTY: post-transplant year.

Figure 2

Survival curves after pancreas transplant. (2a) Pancreas graft survivals after pancreas transplants. Graft loss due to patient death with functioning graft was considered as censor, not event of interest. (2b) Patient survivals after pancreas transplants.